Nature S Sunshine Products Inc Revenue Growth Rates (NATR), Current and Historic Growth - CSIMarket
CSIMarket
 


Nature s Sunshine Products inc   (NASDAQ: NATR)
 

NATR's Revenue Growth by Quarter and Year

Nature S Sunshine Products Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NATR/growth
https://api.csimarket.com/api/v1/companies/NATR/fundamentals
https://api.csimarket.com/api/v1/companies/NATR/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
NATR Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 116.60
2nd Quarter June 116.99
1st Quarter March 121.98
FY 355.57

NATRs Annual Revenue
Nature S Sunshine Products Inc 's Revenue in the fiscal year 2025 $ 479.72 millions
Nature S Sunshine Products Inc 's Revenue in the fiscal year 2024 $ 453.69 millions
Nature S Sunshine Products Inc 's Revenue in the fiscal year 2023 $ 445.13 millions
Nature S Sunshine Products Inc 's Revenue in the fiscal year 2022 $ 421.91 millions
Nature S Sunshine Products Inc 's Revenue in the fiscal year 2021 $ 444.08 millions




NATR Revenue third quarter 2026 Y/Y Growth Comment
Nature S Sunshine Products Inc reported decrease in Revenue in the third quarter 2026 by -8.94% to $ 116.60 millions, from the same quarter in 2025.
The decrease in the third quarter 2026 Nature S Sunshine Products Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 2.42%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 128 other companies have achieved higher Revenue growth. While Nature S Sunshine Products Inc ' s Revenue decline of -8.94% ranks overall at the positon no. 2562 in the third quarter 2026.




NATR Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -8.94 %
2nd Quarter June 2.35 %
1st Quarter March 8.33 %
FY   -

Financial Statements
Nature S Sunshine Products Inc 's third quarter 2026 Revenue $ 116.60 millions NATR's Income Statement
Nature S Sunshine Products Inc 's third quarter 2025 Revenue $ 128.05 millions Quarterly NATR's Income Statement


NATR Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.33 %
2nd Quarter June -4.09 %
1st Quarter March -2.24 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #129
Healthcare Sector #367
Overall #2562

Revenue Y/Y Growth Statistics
High Average Low
24.85 % 2.42 % -16.12 %
(Mar 31 2022)   (Dec 31 2015)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #129
Healthcare Sector #367
Overall #2562
Revenue Y/Y Growth Statistics
High Average Low
24.85 % 2.42 % -16.12 %
(Mar 31 2022)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nature S Sunshine Products Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
14.85 % 0.46 % -9.01 %
(Sep 30 2020)  


NATR's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Nature S Sunshine Products Inc disclosed decrease in Revenue from the second quarter by -0.33% to $ 116.60 millions, from $ 116.99 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Nature S Sunshine Products Inc 's Revenue growth quarter on quarter, overall rank is 2377.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #298
Overall #2377
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #298
Overall #2377
Revenue Q/Q Growth Statistics
High Average Low
14.85 % 0.46 % -9.01 %
(Sep 30 2020)  


NATR's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Nature S Sunshine Products Inc disclosed decrease in Revenue from the second quarter by -0.33% to $ 116.60 millions, from $ 116.99 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Nature S Sunshine Products Inc 's Revenue growth quarter on quarter, overall rank is 2377.


Nature S Sunshine Products Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 491.79
Y / Y Revenue Growth (TTM) 6.98 %
Year on Year Revenue Growth Overall Ranking # 2184
Seqeuential Revenue Change (TTM) 0.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 2551


Cumulative Revenue growth Comment
Assuming the Nature S Sunshine Products Inc 's fiscal year would have ended in Jun 30 2026, Nature S Sunshine Products Inc would have reprted above average annual Revenue improvement of 6.98% year on year, of $ 492 millions.
This marks a slow-down of the companys growth trends and from the 7.42% growth in Mar 31 2026.

In the Healthcare sector 322 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1998 to 2184.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 323
Overall # 2184

Revenue TTM Y/Y Growth Statistics
High Average Low
15.43 %
2.18 %
-12.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2551
Cumulative Revenue growth Comment
Assuming the Nature S Sunshine Products Inc 's fiscal year would have ended in Jun 30 2026, Nature S Sunshine Products Inc would have reprted above average annual Revenue improvement of 6.98% year on year, of $ 492 millions.
This marks a slow-down of the companys growth trends and from the 7.42% growth in Mar 31 2026.

In the Healthcare sector 322 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1998 to 2184.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 323
Overall # 2184

Revenue TTM Y/Y Growth Statistics
High Average Low
15.43 %
2.18 %
-12.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2551




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NATR's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Nature S Sunshine Products Inc Revenue Growth Rates (NATR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Natures Sunshine Products Inc (CIK 275053).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-070270
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Natures Sunshine Products Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.